Purpose: this demonstrator supports strategic exploration. It is not a validated HTA model, reimbursement submission or country-specific legal opinion. All outputs are synthetic and assumption-dependent.
Defensible list-price corridor
—
Modelled range after evidence and negotiation adjustments.
—
Probable negotiated net price
—
List price after mandatory discount and confidential rebate.
HTA acceptance probability
—
Indicative probability based on cost-effectiveness, uncertainty and budget impact.
—
Incremental cost-effectiveness ratio
—
Incremental treatment cost divided by incremental QALYs.
Year 1 net budget impact
—
Treated population × incremental net cost, after avoided costs.
—
Expected Year 1 net revenue
—
Net realised price × expected treated population.
Price–acceptance curve
Indicative reimbursement probability across alternative annual list prices.
Acceptance probability
Current proposed price
Defensible corridor
Country decision context
| Market | |
|---|---|
| Reference value threshold | |
| Budget sensitivity | |
| Negotiation pressure | |
| Comparator adjustment | |
| Evidence confidence factor |
Value-driver sensitivity
Relative effect of each variable on the achievable price.
Scenario comparison
| Scenario | Net price | HTA probability | Budget impact |
|---|